To neither bleed nor clot: That is the question.
Patients with atrial fibrillation (AF) when stented with thin-strut colbalt chrome stents may have a similar outcome to patients without AF. Management of patients with AF potentially place patients at enhanced bleeding risk with triple antithrombotic therapy, or potential thrombotic risk if either oral anticoagulation is held or anti-platelet therapy is truncated. Guideline-based oral anticoagulation for AF is expanding this patient group presenting to the cardiac catheterization laboratory, yet management decisions are still based on limited studies and rely on expert concensus.
Division of Cardiology, Penn State University, College of Medicine, Heart and Vascular Institute, MS Hershey Medical Center, Hershey, Pennsylvania.
Rhian E
RE
Davies
Division of Cardiology, Penn State University, College of Medicine, Heart and Vascular Institute, MS Hershey Medical Center, Hershey, Pennsylvania. icg1@psu.edu.
Ian C
IC
Gilchrist
D000925:Anticoagulants; D001281:Atrial Fibrillation / Q000139:chemically induced; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D010975:Platelet Aggregation Inhibitors; D020521:Stroke / Q000139:chemically induced; D016896:Treatment Outcome
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors
anticoagulants/antithrombins; antiplatelet therapy; clinical trials; percutaneous coronary intervention; stent design/structure/coatings